MedTrace Logo

BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients

NCT03943940 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-05-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the preliminary safety and efficacy of autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) infusion in type 2 Diabetes Mellitus patients.

Conditions

Interventions

BIOLOGICAL

BM-MNC and UC-MSC

Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease. UC-MSC: 1-2 x 10\^6 cells/kg

OTHER

Control

Standard medicine

Sponsors & Collaborators

  • Van Hanh General Hospital

    lead OTHER

Principal Investigators

  • Phuong Thi-Bich Le, MSc-MD · Stem Cell Unit, Van Hanh General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-24
Primary Completion
2019-12-30
Completion
2020-08-30

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03943940 on ClinicalTrials.gov